Emerging Treatment Options for the Management of Metastatic Colorectal Cancer

The addition of new therapies based on the results of biomarker testing has substantially expanded the treatment options for mCRC in recent years, raising new questions about how to select the most appropriate therapy for a specific patient based on their biomarker testing results and how to optimally sequence these therapies. Education is needed to help clinicians understand which biomarkers and other criteria should be considered during treatment decision-making in this rapidly evolving landscape. Getting the right treatment to the right patients and utilizing optimal treatment strategies can maximize benefits while minimizing harms, giving patients with mCRC the best quality and quantity of life possible.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Review criteria for treatment selection in patients with metastatic colorectal cancer, including interpretation of results from biomarker testing.
  • Explain results of recent clinical trials of systemic therapies for patients with metastatic colorectal cancer.
  • Evaluate emerging treatment options and approaches that may improve outcomes in patients with metastatic colorectal cancer.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • BeiGene, Ltd.
  • Celgene Corporation
  • Daiichi Sankyo, Inc.
  • Eisai
  • Genentech, a member of the Roche Group
  • Ipsen Biopharmaceuticals, Inc.
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Jazz Pharmaceuticals, Inc.
  • Lilly
  • Novartis
  • NOVOCURE
  • Pfizer Inc.
  • Puma Biotechnology
  • Sanofi Genzyme
  • Taiho Oncology, Inc.
  • TESARO, a GSK Company

 This activity is supported by independent medical education grants from:

  • Bristol-Myers Squibb
  • Illumina, Inc.

This activity is supported by independent educational grants from:

  • AbbVie
  • Astellas
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Incyte
  • Merck & Co., Inc.

This activity is supported by a medical education grant from Exelixis, Inc.

This activity is supported by an unrestricted educational grant from Kite, a Gilead Company

This project has been made possible in part by a grant from the Varian Medical Systems Educational Grant Corporate Fund, an advised fund of Silicon Valley Community Foundation

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
05/15/2020
Course expires: 
03/01/2021
Cost:
$0.00
Part of: 
NCCN 2020 Virtual Annual Conference

Dustin A. Deming, MD
University of Wisconsin Carbone Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses the following relevant financial relationships:
Dustin A. Deming, MD
AbbVie, Inc.: Grant/Research Support
Array BioPharma: Scientific Advisor; Consulting Fee
Bayer HealthCare: Scientific Advisor; Consulting Fee
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support; Consulting Fee
Eli Lilly and Company: Grant/Research Support
EMD Serono: Grant/Research Support
Genentech, Inc.: Scientific Advisor; Consulting Fee
Ipsen: Scientific Advisor; Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Novocure: Scientific Advisor; Consulting Fee
Promega: Scientific Advisor; Consulting Fee
Revolution Medicines: Grant/Research Support
Taiho Parmaceuticals Co., Ltd.: Scientific Advisor; Consulting Fee

NCCN Staff Disclosures 

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein; Gary J. Weyhmuller, MBA, SPHR

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Wui-Jin Koh, MD
IBM Watson Health for Oncology and Genomics; Scientific Advisor

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Mary A. Dwyer, MS, CGC; Deborah A. Freedman-Cass, PhD; Lisa Gurski, PhD; Rashmi Kumar, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-20-059-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit.  Approval is valid until March 1, 2021. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: